30th Portfolio Decision-Making & Prioritisation for Pharma
Pharmaceutical portfolio decision-making is facing structural pressure. Patent expirations, rising development costs, regulatory complexity, and increasing shareholder scrutiny are forcing organisations to reassess how they allocate capital, prioritise assets, and govern investment decisions. At the same time, AI-driven modelling and scenario tools promise better forecasting, but many organisations remain uncertain about data maturity, bias risks, and governance implications.
The Marcus Evans 30th Edition Portfolio Decision-Making & Prioritisation for Pharma conference, taking place on 24-25 September 2026, in Frankfurt, Germany, will bring together senior leaders across portfolio management, PMO, R&D strategy, and commercial functions to explore how pharmaceutical organisations can make faster and more robust portfolio investment decisions in a capital-constrained environment. Sessions will explore asset prioritisation under patent cliff pressure, portfolio governance and decision frameworks, reprioritisation strategies, and the integration of AI-enabled analytics to support more disciplined portfolio management. The agenda will also deliver actionable insights on managing portfolio trade-offs, overcoming governance bottlenecks, and aligning portfolio investments with long-term strategic objectives, helping pharmaceutical organisations improve decision speed, capital allocation discipline, and portfolio performance across complex and regulated development pipelines.
Attending This Premier Marcus Evans Conference Will Enable You to:
- Prioritise assets under funding pressure and patent cliff exposure
- Strengthen value realisation discipline after portfolio approval
- Structure executive portfolio decision through risk-based governance framework
- Bridge leadership expectations during portfolio change to reduce execution risk
- Lead portfolio reprioritisation with transparent executive communication
- Position AI as decision support for portfolio governance to achieve human-led strategic decisions
Best Practices and Case Studies from:
- Tom Halliwell, Board Director, PIPMG, England
- Martin Slezak, Senior Director- Global Program, Viatris, Germany
- Ullas Hiremath, Director- Early Portfolio & Pipeline, Sandoz, Germany
- Bence Tuske, Head of Program Management, Sanofi, Hungary
- Roberta Sassu, Portfolio Reporting Director, Program Strategy & Planning | Global Clinical Operations, Novartis, Switzerland
- Joshua Valdez, Director- Operations IT - Data, Analytics & AI, Digital Transformation Data, Analytics, & AI, AstraZeneca, Spain
pharmaphorum members are entitled to €200 discount! For more information, please contact: Ria Kiayia, Digital Media & PR Marketing Manager, Marcus Evans, at riak@marcusevanscy.com or visit: https://bit.ly/4wJeUxa
